Last reviewed · How we verify
BNT111
BNT111 is a COVID-19 vaccine candidate.
BNT111 is a COVID-19 vaccine candidate. Used for COVID-19 prevention.
At a glance
| Generic name | BNT111 |
|---|---|
| Sponsor | BioNTech SE |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
BNT111 is a mRNA-based vaccine that encodes for the SARS-CoV-2 spike protein, eliciting an immune response to protect against COVID-19. The vaccine uses a lipid nanoparticle to deliver the mRNA to cells, where it is translated into the spike protein and presented to the immune system. This triggers an immune response, providing protection against the virus.
Approved indications
- COVID-19 prevention
Common side effects
- Pain, redness, swelling at injection site
Key clinical trials
- Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (PHASE1)
- A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT111 CI brief — competitive landscape report
- BNT111 updates RSS · CI watch RSS
- BioNTech SE portfolio CI